These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19783899)

  • 1. Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies.
    Donaldson JM; Kari C; Fragoso RC; Rodeck U; Williams JC
    Cancer Biol Ther; 2009 Nov; 8(22):2147-52. PubMed ID: 19783899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.
    Choi BD; Gedeon PC; Kuan CT; Sanchez-Perez L; Archer GE; Bigner DD; Sampson JH
    J Immunol Methods; 2013 Sep; 395(1-2):14-20. PubMed ID: 23806556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion of a murine monoclonal antibody A13 targeting epidermal growth factor receptor to a human monoclonal antibody by guided selection.
    Chang KH; Kim MS; Hong GW; Shin YN; Kim SH
    Exp Mol Med; 2012 Jan; 44(1):52-9. PubMed ID: 22064379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De novo design of antibody complementarity determining regions binding a FLAG tetra-peptide.
    Entzminger KC; Hyun JM; Pantazes RJ; Patterson-Orazem AC; Qerqez AN; Frye ZP; Hughes RA; Ellington AD; Lieberman RL; Maranas CD; Maynard JA
    Sci Rep; 2017 Aug; 7(1):10295. PubMed ID: 28860479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab.
    Voigt M; Braig F; Göthel M; Schulte A; Lamszus K; Bokemeyer C; Binder M
    Neoplasia; 2012 Nov; 14(11):1023-31. PubMed ID: 23226096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
    Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
    Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response.
    Hartmann C; Müller N; Blaukat A; Koch J; Benhar I; Wels WS
    Oncogene; 2010 Aug; 29(32):4517-27. PubMed ID: 20514015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-EGFR biparatopic-SEED antibody has enhanced combination-activity in a single molecule.
    Kelton C; Wesolowski JS; Soloviev M; Schweickhardt R; Fischer D; Kurosawa E; McKenna SD; Gross AW
    Arch Biochem Biophys; 2012 Oct; 526(2):219-25. PubMed ID: 22426455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8.
    Li S; Kussie P; Ferguson KM
    Structure; 2008 Feb; 16(2):216-27. PubMed ID: 18275813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies.
    Donaldson JM; Zer C; Avery KN; Bzymek KP; Horne DA; Williams JC
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17456-61. PubMed ID: 24101516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pentamerisation of a scFv directed against TRAIL receptor 2 increases its antitumour efficacy.
    Wang W; He W; Wang L; Zhang G; Gao B
    Immunol Cell Biol; 2013 May; 91(5):360-7. PubMed ID: 23567896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.
    Schmiedel J; Blaukat A; Li S; Knöchel T; Ferguson KM
    Cancer Cell; 2008 Apr; 13(4):365-73. PubMed ID: 18394559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and Generation of Humanized Single-chain Fv Derived from Mouse Hybridoma for Potential Targeting Application.
    Khantasup K; Chantima W; Sangma C; Poomputsa K; Dharakul T
    Monoclon Antib Immunodiagn Immunother; 2015 Dec; 34(6):404-17. PubMed ID: 26683180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells.
    Mamot C; Ritschard R; Küng W; Park JW; Herrmann R; Rochlitz CF
    J Drug Target; 2006 May; 14(4):215-23. PubMed ID: 16777680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-depth biophysical analysis of interactions between therapeutic antibodies and the extracellular domain of the epidermal growth factor receptor.
    Alvarenga ML; Kikhney J; Hannewald J; Metzger AU; Steffens KJ; Bomke J; Krah A; Wegener A
    Anal Biochem; 2012 Feb; 421(1):138-51. PubMed ID: 22085444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SNAP-Tag Technology: A Useful Tool To Determine Affinity Constants and Other Functional Parameters of Novel Antibody Fragments.
    Niesen J; Sack M; Seidel M; Fendel R; Barth S; Fischer R; Stein C
    Bioconjug Chem; 2016 Aug; 27(8):1931-41. PubMed ID: 27391930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions between anti-ErbB2 antibody A21 and the ErbB2 extracellular domain provide a basis for improving A21 affinity.
    Chang L; Zhou C; Xu M; Liu J
    J Comput Aided Mol Des; 2010 Jan; 24(1):37-47. PubMed ID: 20012671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paper Title "Hu7CG2: A Novel Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Biparatopic Nanobody".
    Sharifi J; Khirehgesh MR; Akbari B; Soleymani B; Mansouri K
    Mol Biotechnol; 2021 Jun; 63(6):525-533. PubMed ID: 33772436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor.
    Koefoed K; Steinaa L; Søderberg JN; Kjær I; Jacobsen HJ; Meijer PJ; Haurum JS; Jensen A; Kragh M; Andersen PS; Pedersen MW
    MAbs; 2011; 3(6):584-95. PubMed ID: 22123060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Combination of Structural and Empirical Analyses Delineates the Key Contacts Mediating Stability and Affinity Increases in an Optimized Biotherapeutic Single-chain Fv (scFv).
    Tu C; Terraube V; Tam AS; Stochaj W; Fennell BJ; Lin L; Stahl M; LaVallie ER; Somers W; Finlay WJ; Mosyak L; Bard J; Cunningham O
    J Biol Chem; 2016 Jan; 291(3):1267-76. PubMed ID: 26515064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.